KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacific Biosciences Of California (PACB) Finished Goods (2016 - 2025)

Pacific Biosciences Of California (PACB) has 15 years of Finished Goods data on record, last reported at $15.7 million in Q4 2025.

  • For Q4 2025, Finished Goods rose 11.56% year-over-year to $15.7 million; the TTM value through Dec 2025 reached $15.7 million, up 11.56%, while the annual FY2025 figure was $15.7 million, 11.56% up from the prior year.
  • Finished Goods reached $15.7 million in Q4 2025 per PACB's latest filing, down from $16.4 million in the prior quarter.
  • Across five years, Finished Goods topped out at $19.8 million in Q2 2023 and bottomed at $3.7 million in Q2 2021.
  • Average Finished Goods over 5 years is $12.6 million, with a median of $14.4 million recorded in 2024.
  • Peak YoY movement for Finished Goods: crashed 35.22% in 2021, then surged 151.65% in 2023.
  • A 5-year view of Finished Goods shows it stood at $8.0 million in 2021, then skyrocketed by 52.35% to $12.2 million in 2022, then rose by 29.28% to $15.7 million in 2023, then dropped by 10.57% to $14.1 million in 2024, then grew by 11.56% to $15.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Finished Goods were $15.7 million in Q4 2025, $16.4 million in Q3 2025, and $14.8 million in Q2 2025.